Acta Pharm. 68 (2018) 19-30
Meta-analysis review
Efficacy of nucleoside analogues on
hepatitis B virus-related liver failure:
A network meta-analysis
JIAN WU, FANG YIN and XINMIN ZHOU
Digestion Internal Medicine Department, Xijing Hospital, The First Affiliated Hospital of the
Fourth Military Medical University, 127 West Changle
Road, Xi’an, Shaanxi 710000, China
Accepted December 4, 2017
Published online January
25, 2018
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment.
Keywords: liver failure, hepatitis B virus, nucleoside
analogue, tenofovir, network meta-analysis